PI3K inhibitors: Efficacy in diverse cancer forms

One promising target for creating new anticancer medications is phosphatidyl-inositol-3-kinase (PI3K). Many human malignancies, including brain, colon, endometrial, breast, and prostate cancers, have been linked to PI3K dysregulation. The genes for PIK3CA, PIK3CB, PIK3CD, and PIK3CG are encoded by the various isoforms of the PI3K kinase, which are α, β, δ, and γ. Present treatments fail to alleviate symptoms because of certain gene mutations or protein overexpression. There have been encouraging therapeutic findings from using many newly discovered inhibitors of the PI3K signaling pathway, which target different isoforms of the kinase. Several inhibitors with medicinally privileged scaffolds have been developed to target the PI3K pathway or a specific isoform. The PI3K inhibitors GDC-0032 and INK1117 for PI3K-α and AZD8186 for PI3K-β are now being studied in clinical trials. Research on the clinical development, therapeutic utility, and structural insights of new PI3K inhibitors is the main emphasis of this review. The inhibitors have been shown promising anticancer activity relationships.